DIMO Healthcare, the healthcare arm of the leading diversified conglomerate DIMO, together with ZEISS, a globally renowned technology enterprise operating in the optics and optoelectronics sphere, introduced ZEISS CT LUCIA 621P Monofocal Intraocular Lens (IOL) to Sri Lanka. This innovation redefines cataract surgery procedures, offering enhanced visual outcomes for patients.
As part of the ZEISS cataract workflow solution portfolio, the CT LUCIA 621P Monofocal IOL will also empower surgeons with the tools needed to deliver optimized visual outcomes for cataract patients. The fully preloaded injector will make the surgical procedure intuitive, smooth, and controlled, reducing the risk of complications. The architecture of the IOL has been meticulously designed to promote effortless centring and optimize direct contact with the capsular bag. This deliberate design not only assures stability but also maintains a consistent placement within the eye’s natural bag, offering patients a dependable and enduring solution.
Speaking at the launch event, Mr. Vikas Saxena, Regional Head – SAARC, ZEISS Group said, “We are thrilled to introduce the ZEISS CT LUCIA 621P Monofocal IOL to the Sri Lankan market. This innovative IOL is the result of our unwavering commitment to advancing eye care technology and enhancing the quality of life for cataract patients. With its patented ZO Asphericity Concept and user-friendly design, we believe this product will empower surgeons in Sri Lanka to deliver exceptional visual outcomes. ZEISS has a long-standing reputation for delivering cutting-edge optical solutions, and this latest innovation solidifies our commitment to providing state-of-the-art technology to the ophthalmic community in Sri Lanka.”
The ZEISS CT LUCIA 621P Monofocal IOL is a remarkable addition to the world of ophthalmology, featuring the patented ZEISS Optic (ZO) Asphericity Concept. This innovative technology is designed to address a wide range of spherical aberrations, ensuring superior visual outcomes even in cases of potential lens misalignments and decentration. This ground-breaking feature sets the CT LUCIA 621P apart as a true game-changer in the field of cataract surgery.
In addition to this latest launch, ZEISS will also introduce technologically advanced IOLs like Trifocal and Extended Depth of Focus (EDOF) in a phased manner, which will ensure the best patient outcomes for ophthalmologists in Sri Lanka.
Cataract surgery is one of the most common surgical procedures in the world, and the introduction of the ZEISS CT LUCIA 621P Monofocal IOL promises to make this procedure even more effective and reliable.
Learn more about the CT LUCIA® 621P Monofocal IOL from ZEISS.
END
Image Caption
(Left to Right) – Dr.Ishtiaque Anwar, Assistant Professor, Bangladesh Eye Hospital & Institute; Mr. Wijith Pushpawela, Executive Director of DIMO; Mr.Vikas Saxena, Regional Head (SAARC), ZEISS Group; Mr.Ranjith Pandithage, Chairman of DIMO; Mr.Gahanath Pandithage, Managing Director & Group CEO of DIMO; Mr.Priyantha Dissanayake, COO of DIMO Healthcare.
About DIMO
DIMO is a leading diversified conglomerate in Sri Lanka. With its corporate purpose of fuelling dreams and aspirations of the communities it serves, DIMO is committed to creating value responsibly by building partnerships that last generations. Since its inception over eight decades ago, the company has been driven by perfect partnerships, having diversified into wide spectrums of sectors including Agriculture, Building Services, Construction, Digital, Education, Healthcare, Home & Garden, Industrial, Mobility, Power, Energy & Water. DIMO provides world-class solutions and represents the best-engineered brands in the world while adding value and convenience to the lifestyles of consumers in a responsible and ethical manner.
About ZEISS Group
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 8.8 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2022).
For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses,and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market
leadership. ZEISS invests 13 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 38,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2022). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
For further media queries, please contact:
Kajal Kamal | +91 9592870715 | [email protected]